Application Technical Details


Other News


News: Philips and VPDiagnostics team up in MRI of carotid artery athersclerosis

June 16, 2010

Philips Medical Systems and VPDiagnostics, Inc. have  signed a co-marketing agreement. Under this agreement, VPDiagnostics will provide its FDA 510 (k) cleared carotid artery atherosclerosis analysis package, called MRI-PlaqueViewTM, for Philips MRI customers .  Philips has developed an ExamCard for carotid artery imaging on the 3.0 Tesla Acheiva (including Achieva 3.0T, Achieva 3.0T TX, and Achieva 3.0T X-series), the scans have been optimized for image quality and efficient use of scanner  and MRI-PlaqueViewTM.

About Royal Philips Electronics

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in healthcare, lifestyle and technology, delivering products, services and solutions through the brand promise of “sense and simplicity.” Headquartered in the Netherlands, Philips employs approximately 121,700

employees in more than 60 countries worldwide. With sales of USD 34 billion (EUR 27 billion) in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions, personal care and home appliances, as well as consumer electronics. News from Philips is located at

About VPDiagnostics, Inc. ( )

VPDiagnostics, Inc. develops evidence-based imaging solutions to non-invasively diagnose high-risk atherosclerotic plaque before rupture.  It can assist clinicians in planning for the most suitable treatment. It also enables faster and more reliably quantitative detection of disease progression in medical research and drug development. VPDiagnostics’ lead product, MRI-PlaqueViewTM, enables researchers and clinicians to efficiently interpret MRI studies of carotid artery atherosclerosis.  The software has advanced tools to highlight plaque features, including automatic multi-contrast weighting MR registration, vessel morphology delineation, plaque burden analysis, semi-automatic plaque delineation and characterization, and to generate concise reports.  VPDiagnostics is also organizing an NIH-sponsored multi-center prospective clinical trial to evaluate a new diagnostic utility for use with MRI-PlaqueViewTM that will enable the prediction of future risk of stroke and related neurological complications based on plaque characteristics.

Mike Hartmann